The laboratory focuses on basic research in the field of hematooncology, specifically Myelodysplastic Syndromes, Acute Myeloid Leukemia, but also in the field of lymphoproliferations including Multiple Myeloma.
Specifically, the laboratory investigates issues of therapeutic resistance of cancer stem cells and their clonal selection, as well as the specific mechanisms by which tumor bypasses the antitumor effect and how gene expression in resistant cells is specifically reprogrammed to specific therapeutic agents. The lab utilizes OMICs technology in addition to molecular biology approaches, and in addition to cellular models, creates personalized mouse models of tumorigenesis, so-called 'patient-derived xenografts' (PDX), for the investigation of new therapeutic agents and approaches.
- Understand the mechanisms of resistance in epigenetic therapy with hypomethylating agents in Myelodysplastic Syndrome.
- To uncover novel mechanisms of clonal selection of Plasmacytoma cells in the presence of proteasome inhibitors.
- To understand the epigenetic mechanisms of normal and tumor biology in early stem cell differentiation.